<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/124AFE1F-3311-4FCE-BA16-A5BAD5387B6B"><gtr:id>124AFE1F-3311-4FCE-BA16-A5BAD5387B6B</gtr:id><gtr:name>Kyoto Prefectural University of Medicine</gtr:name><gtr:address><gtr:line1>Department of Ophthalmolgy</gtr:line1><gtr:line2>Kyoto Prefectural University of Medicine</gtr:line2><gtr:line3>Kawaramachi hi rokoji</gtr:line3><gtr:postCode>602 0841</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68738831-599A-42BB-8DFA-64269BB8CA24"><gtr:id>68738831-599A-42BB-8DFA-64269BB8CA24</gtr:id><gtr:name>Tokyo Research Institute of Psychiatry</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9EED95BB-25DC-4032-8E45-C3EA7277E78A"><gtr:id>9EED95BB-25DC-4032-8E45-C3EA7277E78A</gtr:id><gtr:name>University of Milan</gtr:name><gtr:address><gtr:line1>Via Festa del Perdono 7</gtr:line1><gtr:postCode>20122</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F"><gtr:id>FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F</gtr:id><gtr:name>Northwestern University</gtr:name><gtr:address><gtr:line1>633 Clark Street</gtr:line1><gtr:postCode>60208</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89D5574C-AAF7-4D96-832C-C2BA623123CE"><gtr:id>89D5574C-AAF7-4D96-832C-C2BA623123CE</gtr:id><gtr:name>Eberhard Karls University Tuebingen</gtr:name><gtr:address><gtr:line1>Wilhelmstra?e 7</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/44160F04-5CBF-4E8E-A6C6-C0EF61A5865C"><gtr:id>44160F04-5CBF-4E8E-A6C6-C0EF61A5865C</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:department>Lancaster Environment Centre</gtr:department><gtr:address><gtr:line1>University House</gtr:line1><gtr:line4>Lancaster</gtr:line4><gtr:line5>Lancashire</gtr:line5><gtr:postCode>LA1 4YW</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/44160F04-5CBF-4E8E-A6C6-C0EF61A5865C"><gtr:id>44160F04-5CBF-4E8E-A6C6-C0EF61A5865C</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>University House</gtr:line1><gtr:line4>Lancaster</gtr:line4><gtr:line5>Lancashire</gtr:line5><gtr:postCode>LA1 4YW</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/124AFE1F-3311-4FCE-BA16-A5BAD5387B6B"><gtr:id>124AFE1F-3311-4FCE-BA16-A5BAD5387B6B</gtr:id><gtr:name>Kyoto Prefectural University of Medicine</gtr:name><gtr:address><gtr:line1>Department of Ophthalmolgy</gtr:line1><gtr:line2>Kyoto Prefectural University of Medicine</gtr:line2><gtr:line3>Kawaramachi hi rokoji</gtr:line3><gtr:postCode>602 0841</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68738831-599A-42BB-8DFA-64269BB8CA24"><gtr:id>68738831-599A-42BB-8DFA-64269BB8CA24</gtr:id><gtr:name>Tokyo Research Institute of Psychiatry</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9EED95BB-25DC-4032-8E45-C3EA7277E78A"><gtr:id>9EED95BB-25DC-4032-8E45-C3EA7277E78A</gtr:id><gtr:name>University of Milan</gtr:name><gtr:address><gtr:line1>Via Festa del Perdono 7</gtr:line1><gtr:postCode>20122</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F"><gtr:id>FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F</gtr:id><gtr:name>Northwestern University</gtr:name><gtr:address><gtr:line1>633 Clark Street</gtr:line1><gtr:postCode>60208</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89D5574C-AAF7-4D96-832C-C2BA623123CE"><gtr:id>89D5574C-AAF7-4D96-832C-C2BA623123CE</gtr:id><gtr:name>Eberhard Karls University Tuebingen</gtr:name><gtr:address><gtr:line1>Wilhelmstra?e 7</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4DD30DDB-46FD-464E-B1C5-B9895F852981"><gtr:id>4DD30DDB-46FD-464E-B1C5-B9895F852981</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Diggle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/56719655-92CF-4CA0-A0F4-842C566ACCCE"><gtr:id>56719655-92CF-4CA0-A0F4-842C566ACCCE</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Allsop</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CF30D538-3C97-4AD2-B0DE-F35407ABC3BD"><gtr:id>CF30D538-3C97-4AD2-B0DE-F35407ABC3BD</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Mann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CB234782-E0C2-4EC4-B425-23DB5741EEED"><gtr:id>CB234782-E0C2-4EC4-B425-23DB5741EEED</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Douglas</gtr:otherNames><gtr:surname>Mitchell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601364"><gtr:id>0EC3E5AE-BAE0-43F8-AE17-99E38B980B95</gtr:id><gtr:title>Development of alpha-synuclein as a potential molecular marker for Parkinson s disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601364</gtr:grantReference><gtr:abstractText>Parkinson?s disease (PD) is a common, incurable brain disease, with characteristic symptoms including tremors of the hands, muscle rigidity and slowness of movement. In PD, structures called ?Lewy bodies? are found inside nerve cells in affected regions of the brain. Lewy bodies contain abnormal fibres made out of a protein called alpha-synuclein and the formation of these alpha-synuclein deposits inside Lewy bodies is an important step in the development of PD. Interestingly, we have found that alpha-synuclein is also present in human blood. Furthermore, the levels of this protein appear to be altered in blood samples from patients with PD. We now propose to set up an extensive study to determine if alpha-synuclein in blood can be used as a diagnostic marker to help to discriminate PD from other movement disorders, or to follow the clinical progression of the disease. We will also run a clinical trial on a potential new drug for PD and as part of this trial we will monitor the effects of this drug on alpha-synuclein levels in blood. This will help us to determine if alpha-synuclein can be used as a marker in many future drug trials. Ultimately, it is hoped that a blood test can be developed to allow detection of PD during its early stages, when treatment is likely to be most effective. The development of alpha-synuclein as a biological marker would be expected to lead to major improvements in the treatment and quality of life of people with PD.</gtr:abstractText><gtr:technicalSummary>This proposal is focussed around the development of a protein called alpha-synuclein as a potential novel molecular marker for Parkinson?s disease (PD). This protein plays a key role in the histopathology and genetics of PD, and we have discovered that alpha-synuclein is present in human body fluids, including blood plasma. Recently, we have published preliminary evidence, involving relatively small scale studies, that the levels of this protein in cerebrospinal fluid and blood plasma are altered in patients with PD compared to controls, and that these levels can correlate with the clinical severity of disease. We now propose to carry out an extensive investigation into both normal and pathological forms of alpha-synuclein as a potential biomarker for the diagnosis and/or progression of PD. To assess the reliability of alpha-synuclein as a diagnostic marker, our ELISA methods will be refined so that we can reliably measure the levels of various forms of alpha-synuclein (e.g. total, oligomeric) in blood plasma samples. Blood samples will be collected from at least 300 cases of idiopathic PD and 600 neurological and non-neurological controls. Repeat blood samples will also be taken from some cases of PD for longitudinal studies to investigate if the levels of alpha-synuclein change progressively with the clinical course of the disease (to be monitored by clinical rating scales). These latter studies will determine if alpha-synuclein can be used as a surrogate marker for disease progression. This would be particularly useful for streamlining the testing of new drugs in clinical trials. This research will be carried out by a multi-disciplinary team involving neuroscientists, clinicians and statisticians/epidemiologists from Lancaster and Manchester Universities, and major clinical neuroscience units based in Manchester and Preston, in close collaboration with Zyentia, a small biotechnology company who specialise in the development of novel drugs for ?protein folding? disorders. As an integral part of the project, Zyentia will provide samples from animal models of PD for biomarker studies. They will also organise and fund a phase II clinical trial on one of their lead compounds, a novel inhibitor of alpha-synuclein aggregation, which will use alpha-synuclein as a surrogate marker for PD in combination with standard disease rating scales. It is expected that this trial will gauge the potential of alpha-synuclein as a surrogate biomarker for future clinical studies in PD, perhaps facilitating the development of new and improved therapies for this condition.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>393109</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eberhard Karls University of Tubingen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>EU Framework 7, Marie Curie Training Network</gtr:description><gtr:id>8934A02C-BE64-4F09-9C93-FF876EC1FDD8</gtr:id><gtr:impact>EU Framework 7, Marie Curie Training Network (11 collaborating partners), Academic-Industrial Training Network on Alpha-Synuclein-related Brain Diseases (NEURASYN), ?4,770,000 (Lancaster share, ?205,000), commenced October 2009. This is a multidisciplinary collaboration, involving partners with expertise in the cell and molecular biology of alpha-synuclein, human genetics and animal models.</gtr:impact><gtr:outcomeId>1EC261CE440-1</gtr:outcomeId><gtr:partnerContribution>Partners on 2009-2013 EU Framework 7, Marie Curie Training Network (11 collaborating partners), Academic-Industrial Training Network on Alpha-Synuclein-related Brain Diseases (NEURASYN), ?4,770,000 (Lancaster share, ?205,000).</gtr:partnerContribution><gtr:piContribution>Partner on EU Framework 7, Marie Curie Training Network, looking at the different forms of alpha-synuclein that are present in human blood plasma.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kyoto Prefectural University of Medicine</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Research collaboration investigating biomarkers</gtr:description><gtr:id>02E8B72E-95E1-4980-9399-21DFE6FCB818</gtr:id><gtr:impact>Publication 18989684. Dr. Kasai is a visiting scientist at Lancaster University. He is studying molecular biomarkers in neurodegenerative disease, for 24 months, commencing July 2010. Data also presented at 19th International Symposium on ALS/MND in Birmingham, 2008.</gtr:impact><gtr:outcomeId>D8200368BE4-1</gtr:outcomeId><gtr:partnerContribution>Drs. Kasai, Tokuda, Ishigami, Sasayama and Nakagawa were co-authors and investigators on our paper 18989684. They provided clinical samples and data for this paper.</gtr:partnerContribution><gtr:piContribution>Prof. Allsop and Dr. Foulds (Lancaster), Prof. Mann (Manchester) and Prof. Mitchell (Royal Preston Hospital) provided expertise and supplementary data for this study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northwestern University Chicago</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Feinberg School of Medicine</gtr:department><gtr:description>Research collaboration correlating brain pathology with biomarkers</gtr:description><gtr:id>3572C262-F1CE-4264-A6C2-46582AEC3B71</gtr:id><gtr:impact>Publication 19823856. Data also presented at The British Neuropathological Society Meeting in London, January 2009.</gtr:impact><gtr:outcomeId>89908456FD1-1</gtr:outcomeId><gtr:partnerContribution>Co-authors on 19823856. Drs. Mishra, Johnson, Weintraub and Bigio provided clinical samples (brain and plasma) for our investigation.</gtr:partnerContribution><gtr:piContribution>We carried out the measurements of biomarkers in plasma (Lancaster University), and correlated this with histopathology in matching brain tissue samples (Manchester University). The collaboration is ongoing, with more brain and plasma samples and relevant histopathology data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tokyo Research Institute of Psychiatry</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Provision of novel antibodies and protein standard for biomarker studies</gtr:description><gtr:id>74CAE5EC-1B71-4144-972A-BCFA78D76243</gtr:id><gtr:impact>Publications 19823856, 21865317, 21856424. Collaboration continues, with this group providing antibodies to phosphorylated alpha-synuclein, which are being currently investigated. Data also presented at British Neuropathological Society (BNS), London, January 2008; BNS January 2010; World Parkinson's Congress, Glasgow, October 2010; Parkinson's UK Conference, November 2010.</gtr:impact><gtr:outcomeId>3DB088EB3B1-1</gtr:outcomeId><gtr:partnerContribution>Drs. Akiyama, Arai and Hasegawa provided novel antibodies for biomarker discovery.</gtr:partnerContribution><gtr:piContribution>We used the novel antibodies to investigate new biomarkers in human plasma. Phosphorylated alpha-synuclein supplied by the collaborators has been used as a standard for novel ELISA development.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Milan</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>EU-Framework 7 Grant, NAD</gtr:description><gtr:id>5948529A-8E5F-43CF-B071-F87A8E56C7D1</gtr:id><gtr:impact>2008-2012, EU Framework 7, Specific Targeted Research Project (19 collaborating partners), total value ?11,110,000 (Lancaster share ?314,000). Multidisciplinary collaboration, involving partners with expertise in nanoscience, brain imaging, animals models, and amyloid biochemistry.</gtr:impact><gtr:outcomeId>2925AB88140-1</gtr:outcomeId><gtr:partnerContribution>Has resulted in large EU Framework 7, Specific Targeted Research Project (19 collaborating partners), on Nanoparticles for the diagnosis and therapy of neurodegenerative disease (NAD), ?11,110,000 (Lancaster share ?314,000).</gtr:partnerContribution><gtr:piContribution>Partner on large EU-FP7 grant, investigating nanoparticles for early diagnosis and treatment of neurodegenerative disease. We are assessing the effects of the nanoparticles on protein aggregation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MNDA Symposium Preston</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B9B9C0F1-590E-4B26-AB33-428937E0BB18</gtr:id><gtr:impact>Prof. Allsop presented work on biomarkers and disease

Generated interest in further collection of clinical samples</gtr:impact><gtr:outcomeId>B43F1FF456B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancaster University Women's Association talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7E3A63A3-54C3-4A4E-8E08-A3FADA2ADA4C</gtr:id><gtr:impact>40 retired members of the university staff attended a talk by Dr. Foulds on our research into brain diseases.

Many members have reported an interest in participating in studies.</gtr:impact><gtr:outcomeId>dxfLZ5hstRw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Launch Event of 'Lancaster University Centre for Ageing Research (C4AR)'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FFCBA8E9-756D-4BAB-97E5-489420F86658</gtr:id><gtr:impact>Approximately 100 people associated with the newly formed Centre for Ageing Research and interested members of the public attended this meeting. Talks given by both Dr. Penny Foulds and Prof. David Allsop.

Stimulated interest in the C4AR. Publicised research done at Lancaster University into age-related diseases.</gtr:impact><gtr:outcomeId>QxocLbugLnP</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lab Visits, Lancaster University</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F09604DD-6177-4635-A284-0AF049219694</gtr:id><gtr:impact>Dr. Foulds hosted a tour around Prof. Allsop's laboratory, with talks from research staff to explain areas of research.

Invited to give further talks for Department of Continuing Education.</gtr:impact><gtr:outcomeId>2E19BE0B921</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancaster Soroptomist's Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FDE52DBB-DB50-45B6-A852-BF944107E089</gtr:id><gtr:impact>30 professional ladies attended a talk by Dr. Foulds on our research into Parkinson's disease.

The group have asked for a lab visit.</gtr:impact><gtr:outcomeId>h4tnDgv8vgF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancaster Girls' Grammar School Work Experience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F160B0B8-FD12-4D58-B81C-C1362F276F39</gtr:id><gtr:impact>4 sixth form pupils participated in laboratory work at Lancaster University for one week, and were acknowledged on one of our publications.

All four have gone on to do degrees related to medicine.</gtr:impact><gtr:outcomeId>CL54ELPMwCV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Parkinson's UK lancaster Support Network</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C8B641FA-52E1-469C-B0C3-F5DEB43A50E0</gtr:id><gtr:impact>40 members of the Lancaster and Morecambe Parkinson's UK Support Network (patients and supporters) attended a talk giving an update on the results of the MRC-funded biomarker study.

The group asked for a lab visiit, which was scheduled for the following Summer.</gtr:impact><gtr:outcomeId>bSYu5YHRpU5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DeNDRoN NW 3rd Annual Conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>22D72F99-EB00-4AAE-AB5B-B1FB9584E68C</gtr:id><gtr:impact>Oral presentations were given by Dr Foulds (Lancaster) and Prof Mann (Manchester) on peliminary results from the MRC-funded longitudinal biomarker studies.

Liaiason with clinical neurologists to encourage patient recruitment onto the MRC-funded study. Dr. Foulds was invited to give talks to patient groups.</gtr:impact><gtr:outcomeId>0A46E06CE41</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AR-UK Visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6BC2118B-1B20-4EAC-8AC8-CAD0B23D9B0F</gtr:id><gtr:impact>Officials from Alzheimer's Research UK visited alongside funding benefactors to hear about plans at Lancaster and Manchester Universities relating to new Luminex Bead equipment for carrying out multiplex assays on samples of blood or CSF.

We were asked by AR-UK to represent the scientific community on matters that may be of interest to the public (e.g. new discoveries about brain diseases).</gtr:impact><gtr:outcomeId>AkKPv7sLs5d</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press coverage</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EDF9C78F-0413-4E61-A946-9D87CC015424</gtr:id><gtr:impact>Prof Allsop and Dr Foulds have had the following press coverage:- The Garstang Courier, September 2008; The Burnley Express, September 2008; The Morecambe Visitor, September 2008; The Lancashire Evening Post, September 2008; Nano Werk website, September 2008; Cordis Wire website, September 2008; The Lancaster and Morecambe Visitor, September 2008; The Lancaster Guardian, September 2008; Clitheroe Advertiser, September 2008; The Clitheroe Advertiser and Times, September 2008; The Lakeland Echo, September 2008; The Blackpool Gazette, November 2008; The Daily Telegraph, February 2009; BBC News Online, February 2009; BBC News Online, June 2009; The Independent. June 2009; Tehran Times, June 2009; The Express, June 2009; Morecambe News, September 2009; Burnley Express, September 2009; Longridge News, September, 2009; Pendle Today, September 2009; Lakeland Echo, September, 2009; Garstang Courier, September 2009; Chorley Guardian, September 2009; BBC WOWT-TV Online, September 2009; Bilingual News, September 2009; TheVisitor.co.uk, September 2009; Blackpool Gazette, September 2009; Lancashire Evening Post, September 2009; Garstang Courier, September 2009; Chorley &amp;amp; Leyland Guardian, September 2009; Pendle Today, September 2009; Longridgenews.co.uk, September 2009; Burnley Express, September 2009; Clitheroe Advertiser &amp;amp; Times, September 2009; Lakeland Echo, September 2009; Lancaster Guardian, September 2009; Clitheroe Advertiser &amp;amp; Times, February, 2010; Lancaster Guardian, February, 2010; Burnley Express, February, 2010; Blackpool Gazette, February, 2010; Lancashire Evening Post, February, 2010; TheVisitor.co.uk, February, 2010; Garstang Courier, February, 2010; Pendle Today, February, 2010; Chorley &amp;amp; Leyland Guardian, February, 2010; Longridgenews.co.uk, February, 2010; Daily Mail, November 2010; Pharma Denmark, August 2011; Medindia.com, August 2011; TopNews, August 2011; TopNews New Zealand, August 2011; Investor Village, August 2011; BBC News - Isle of Mann, August 2011; MediLexicon, August 2011; BioPortfolio, August 2011; Scottish Daily Express, August 2011; Express.co.uk, August 2011; Mirror.co.uk, August 2011; Sporting Life.com, August 2011; Health News, August 2011; Politiken.dk, August 2011; Science Daily, August 2011; The Medical News, August 2011; Alpagalileo, August 2011; The Examiner in Alabama, August 2011; MediLexicon, November, 2011; Medical News Today, November, 2011; LabSpaces.net, November, 2011; EurekAlert!, November, 2011; Best Syndication, November, 2011; London Free Press, November, 2011; KopalniaWiedzy, November, 2011, Lancashire Evening Post, November, 2011.


This has increased regional, national and international awareness of our research into neurodegenerative diseases at Lancaster University.</gtr:impact><gtr:outcomeId>B7720B718C4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Carers' group Meeting - Manchester</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CDDB3196-20FA-46BD-A2AE-6EBF8284CE32</gtr:id><gtr:impact>Prof Mann gave a talk to carers and patients on Neurodegenerative disease, and current research.

The talk raised the profile, and publisesed research carried out on the MRC funded project.</gtr:impact><gtr:outcomeId>4100844FA5E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Senior Learners' Programme, Lancaster University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>13E357CC-3D7E-4364-8E2F-94C73E5D038D</gtr:id><gtr:impact>Dr. Foulds presented an overview of current research into Parkinson's disease with a brief description of research into this disease at Lancaster University.

Dr. Foulds invted to give further talks at similar meetings in the future.</gtr:impact><gtr:outcomeId>7436FF02F37</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's Research UK Visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4FBA9522-5CC0-4F45-B5A9-2B395CC0FC0B</gtr:id><gtr:impact>Members of Alzheimer's Research UK and their donors attended a meeting at Lancaster University which included a tour of the laboratories, and presentations by researchers on biomarkers of neurodegenerative disease.

AR-UK have funded the purchase of a luminex platform (&amp;pound;36k) for multiplex biomarker assays. A repeat visit is being held Summer 2013 to give us the opportunity to update AR-UK and their supporters on results arising from the use of this equipment.</gtr:impact><gtr:outcomeId>D2d9rMMekjx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to Neurology Ward at Royal Preston Hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1D1D01BA-2876-405C-A1F8-2183A517E37F</gtr:id><gtr:impact>Prof. Allsop and Dr. Foulds talked to clinical staff on the ward about their research into biomarkers and encouraged participation in future studies.

Clinical staff are actively collecting samples of blood and CSF (with full LREC Approval). We plan to visit every four months to meet the new SHOs and keep staff up to date with our studies.</gtr:impact><gtr:outcomeId>bEwQsepwFpG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ART Public Meeting (Manchester)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>025F270B-2135-4DFA-AC01-061B2BF2D816</gtr:id><gtr:impact>Around 70 members of the public and carers attended. Dr. Penny Foulds gave a talk explaining the science behind neurodegererative brain diseases.

The talk was exceptionally well received. Dr. Foulds was interviewed on camera for launch of the new ART website in March 2011.</gtr:impact><gtr:outcomeId>LnuZ81PY9WU</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DeNDRoN National Conference Southampton</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F92EB415-DB14-42AE-BEC7-5B6482ED593E</gtr:id><gtr:impact>Prof Mitchell (Royal Preston Hospital) and Angela Aldridge (DeNDRoN research co-ordinator for MRC project) presented a poster publicising the study.

Has helped patients recruitment into the study. The MRC-funded study is now the largest in terms of patient numbers to be adopted by DeNDRoN NW.</gtr:impact><gtr:outcomeId>C14BB7D59EF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parkinson's UK Conference 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8F46C743-895A-4D2E-897C-408D89D5A98D</gtr:id><gtr:impact>Dr. Foulds presented the results of the MRC-funded biomarker study at the Parkinson's UK Research Conference, which was held from 4-6 November 2012, at Royal York Hotel, York (see http://www.parkinsons.org.uk/researchconference). A poster presentation was also made. Title as follows, 'Development of phosphorylated alpha-synuclein as a molecular biomarker in Parkinson's disease' by Foulds, Diggle, Mitchell, Mann and Allsop.

We have been invited to apply for further funding to continue this area of research.</gtr:impact><gtr:outcomeId>KAVJGEix2GA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to MSA Trust, Queen's Square, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>91B2FC34-271B-4379-A7D7-BD871824C117</gtr:id><gtr:impact>About 200 people attended the first meeting of the MSA Trust at Institute of Neurology, UCL, London on 2nd May 2012. MRC-funded work on alpha-synuclein as a biomarker was presented by Dr. Foulds (Lancaster) and Prof. Mann (Manchester).

Offers of collaboration with other research groups.</gtr:impact><gtr:outcomeId>hevC54NpwSk</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with patients recruited onto the MRC biomarker study</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7287BC27-9792-48C8-90DE-609BD360456D</gtr:id><gtr:impact>All 200 participants of the MRC-funded study were invited to Lancaster University to attend a presentation of results arising from the work. About 60 patients, health professionals and post-graduate students attended the meeting.

The participants were exceptionally grateful to be given the opportunity to learn about the results from the study. many of them have offered their help, if required in the future.</gtr:impact><gtr:outcomeId>aTsHivmVxJA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar at Royal Preston Hospital</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C365709C-6782-402B-B101-F73D3FC90781</gtr:id><gtr:impact>Prof. Allsop gave a talk on biomarkers and Parkinson's disease to a group of clinician's at Royal Preston Hospital, organised by Prof. Douglas Mitchell.

Stimulated interest and patient recruitment into MRC-funded project</gtr:impact><gtr:outcomeId>E5F9B1BC32F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to Lancaster University by Lancaster and Morecambe Parkinson's UK Support Group</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5F523A0C-F692-44DB-86C5-F3F347F5E080</gtr:id><gtr:impact>45 Members of Lancaster and Morecambe Parkinson's UK Support Group attended talks given by Prof. Allsop and his PhD students. There was also a tour of our labs.

Members of the group have indicated willingness to volunteer as participants in our future research.</gtr:impact><gtr:outcomeId>LbE1BgP776f</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Preston MND care and Research Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C59E0C4B-2EED-4FC7-83D8-11B0BAB7EF23</gtr:id><gtr:impact>Dr. Penny Foulds explained the causes of neurodegenerative diseases, which was well received by the audience and an extensive question and answer session ensued.

Members of the MNDA are to visit the laboratories at Lancaster University and learn more about diseases of the brain. Also, the group were alerted to the need for brain donations and participation in clinical trails. Members were given details of the ART Manchester Brain Bank and also DeNDRoN.</gtr:impact><gtr:outcomeId>chqdEaN4yTt</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parkinson's Disease Society, Burnley Branch Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AD8B61EE-9D1F-46D2-BDAB-F4DCF337D83E</gtr:id><gtr:impact>40-50 patients and healthworkers attended a talk by Dr. Penny Foulds.

Sparked interest in clinical study participation and tissue donation.</gtr:impact><gtr:outcomeId>pFFXNNs11fE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Morecambe High School Talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6A1BDE9C-97AC-4E96-B67C-F95AFED13ABD</gtr:id><gtr:impact>25 pupils came to visit the university and attended a talk by Dr. Penny Foulds on our research into brain diseases.

Lab visits organised</gtr:impact><gtr:outcomeId>nbTmnBtLjZK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0DD941F7-2C00-4843-A4C1-E0DC13A4DFA1</gtr:id><gtr:impact>40 members of the Blackpool and Fylde Branch of the Motor Neuron Disease Association attended presentations on our research and a guided tour of our labs. The presentations were given by PhD students at Lancaster University.

Fundraising activities for MNDA supported. Invited to give a talk at 2012 Annual Meeting.</gtr:impact><gtr:outcomeId>QLKXp2nFrMx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview on BBC Radio Lancashire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>15822F3C-E566-4AA3-AE3B-D79E07FBE27F</gtr:id><gtr:impact>Prof. Allsop gave an interview that was broadcast live at 8.30am and centred on the MRC-funded research on biomarkers at Lancaster University.

Several offers of assistance regarding recruits onto the study.</gtr:impact><gtr:outcomeId>JCaWg5o6Lyc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancaster and Morecambe University of the Third Age</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>68E8435C-AB02-4D2F-ADF1-429936949AED</gtr:id><gtr:impact>More than 200 members of the public attended a talk by Dr. Foulds, who was voted as 'Most Popular Speaker'.

Raised awareness of neurodegenerative disease, and Penny Foulds was asked to give further talks to other interested groups.</gtr:impact><gtr:outcomeId>LoVJsJujTgs</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DeNDRoN National Conference Newcastle</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F5CA61D9-BCAE-403E-89AA-DEDC93CCC6B7</gtr:id><gtr:impact>A poster was presented on the proposed experimental approach to the MRC-funded study.

Prof. Allsop was invited by Dr. Richard Wyse to give a talk at The Cure For Parkinson's Trust Meeting held at RSM, London (2009). Here we met Dr. David Dexter (PDS brain bank) and arranged access to samples of brain tissue and matching CSF for the MRC-funded biomarker study.</gtr:impact><gtr:outcomeId>375E5341E06</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ART Public Meeting - Nottingham</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B85157F4-2520-42C3-AAD0-C64E76E981BD</gtr:id><gtr:impact>Prof Mann gave a presentation on Biomarkers in Neurodegeneration, focussing on the MRC funded project.

The meeting was well recieved by members of the public, therefore raising the profile of the research carried out at lancaster and Manchester.</gtr:impact><gtr:outcomeId>035782E22E4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancaster Girl's Grammar School Work Experience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BFDF1E49-777A-4220-A277-1D13CFE12E67</gtr:id><gtr:impact>Five pupils did some work experience in the laboratory, relating to Parkinson's disease. One of them was on a formal scheme funded by The Nuffield Foundation.

Confirmed their career choice in Science.</gtr:impact><gtr:outcomeId>saKWqD3egLY</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Parkinson's disease interest group meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2D17AEB0-8CFC-4164-990B-F081D54D9666</gtr:id><gtr:impact>Talk given at a meeting organised by Dr Mark Kellet (consultant neurologist, Hope Hospital, Manchester) by Prof Allsop on biomarkers for Parkinsons disease.

Stimulated recruitment of patients into MRC-funded project.</gtr:impact><gtr:outcomeId>476C721CA6C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio Lancashire Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A1999F32-9744-4A9C-BCDF-3D3F704A0E8C</gtr:id><gtr:impact>Prof. Allsop gave an interview (August 2011) on the research into brain diseases being carried out at Lancaster University that was broadcast on BBC Radio Lancashire and made available as a 'podcast' on their website.

Enquiries regarding participation in our research activities from members of the public.</gtr:impact><gtr:outcomeId>dt4aoB4TFNi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to Lancaster and Morecambe Parkinson's UK Support Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BC600096-A9AC-407B-B5E3-F904C30CBBB7</gtr:id><gtr:impact>40 members of The Lancaster and Morecambe Parkinson's UK Support Group attended their weekly meeting where Dr. Foulds was invited to talk about the MRC-funded research into a biomaker for PD.

They in turn have visited us at Lancaster University. Some members also volunteered to participate in our future studies.</gtr:impact><gtr:outcomeId>qdtZtg8tEa4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit by Parkinson's UK lancaster Support Network and XEED North West</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AA9FEB3B-A920-4E81-8FB1-CF3EC23E42F5</gtr:id><gtr:impact>60 people (patients, carers, supporters, health professionals) attended a presentation by Lancaster University School of Health and Medicine on biomarkers in Parkinson's disease, and psychological problems associated with the disease.

Articles in local press, radio interview and publicity within the university, and online on the university website.</gtr:impact><gtr:outcomeId>EvMYXkw5QVi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Preston Royal Infirmary Neurology Ward</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>84CE0570-2228-4E4E-AF2E-DE28D50A8962</gtr:id><gtr:impact>12 health care professionals (doctors, ward and research nurses) attended a talk and discussion about engagement and collaboration in our reserarch activities.

Agreement to participate in collection of clinical samples.</gtr:impact><gtr:outcomeId>f78kgFD5SbG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancaster University Women's Association</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>25665122-9DE3-44B0-9E51-7F10148989F1</gtr:id><gtr:impact>Attended by 35 members of the public who support research carried out at Lancaster University.

Encouraged audience to consider registering for brain donation.</gtr:impact><gtr:outcomeId>eodgz5jPVja</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture, Lancaster Storey Institute</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>12E17969-6726-4F89-B6DA-5F6D5468E72C</gtr:id><gtr:impact>50 members of the public attended a lecture by Dr. Penny Foulds on Parkinson's disease that was advertised in local papers/local radio.

Lab visit arranged</gtr:impact><gtr:outcomeId>Ahvb7AH81hF</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beijing Summit Forum 2009</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2B67F52B-7B24-40BB-896F-4FE5DE794349</gtr:id><gtr:impact>Dr Foulds (Lancaster) and Prof Mann (Manchester) gave presentations to an audience mainly of Chinese medical students and neurologists presenting preliminary results from the MRC-funded study.

Arrangements are being made for a Chinese research study to carry out a PhD at Lancaster University focussing on biomarker research.</gtr:impact><gtr:outcomeId>EFD41B63BFF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lancaster University PhD Studentship - Development of a luminex multiplex bead assay for biomarkers related to neurodegeneretaive diseases</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Lancaster University</gtr:fundingOrg><gtr:id>60635CE5-15E2-4696-BDA2-69BDFF9F5156</gtr:id><gtr:outcomeId>XrYGafn7zQa</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - A prospective study of the utility of TAR DNA-binding protein (TDP-43) and FUS, their oligomeric and aberrant forms, as biomarkers of motor neuron disease (MND)</gtr:description><gtr:fundingOrg>Sir John Fisher Foundation</gtr:fundingOrg><gtr:id>9A8D6A93-CA9E-4B2F-8208-56EBF2EFCA9D</gtr:id><gtr:outcomeId>qeRg3YzsT4r0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>33568</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AR-UK Equipment Grant - Purchase of Qiagen luminex bead system</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>8B7D7582-7F3B-49B9-957A-54CA9D7CDD73</gtr:id><gtr:outcomeId>nNMcY9mMfSM0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NHS SIFT Masters Studentship - Biomarkers for Parkinson's disease</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>B14924CE-5C7E-4C29-9FF1-5C78F4A21587</gtr:id><gtr:outcomeId>MSvtVGh9BQJ0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36339</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DeNDRoN FSF Funding - Biomarkers for Parkinson's disease</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>E471F9E8-9EA8-45F5-8F79-315CDEAE0D02</gtr:id><gtr:outcomeId>HGhhtzvEZDX0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49681</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pilot Study - Development of a new ?-Amyloid PET tracer for early diagnosis of Alzheimer's disease</gtr:description><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>F917292D-E276-44A9-AB20-8AD7352A4C18</gtr:id><gtr:outcomeId>kFsutmzBSUc</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lancaster University Studentship (Expression of key proteins implicated in neurodegeneration)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Lancaster University</gtr:fundingOrg><gtr:id>3FA3E0CD-759B-4B9F-AB5B-3CE7325ABCAD</gtr:id><gtr:outcomeId>E9F06EB823C0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>330000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - Longitudinal investigation of novel biomarkers and the effects of anti-dementia treatments for Alzheimer's disease</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Sir John Fisher Foundation</gtr:fundingOrg><gtr:id>ECC8F303-0444-404D-B018-3B4697E22D81</gtr:id><gtr:outcomeId>0EDE69F30590</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>George Barton Trust, Project Grant - Research into biomarkers for neurodegenerative disease</gtr:description><gtr:fundingOrg>George Barton Trust</gtr:fundingOrg><gtr:id>9DDC2E22-8C3E-4210-A673-999D102ACCEE</gtr:id><gtr:outcomeId>187F069C7000</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Use of Multiple Biomarkers to Stratify Parkinsonian, Alzheimer and Frontotemporal Dementias</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>CE97B11E-0B0C-425C-9BF5-2AA57DA02B28</gtr:id><gtr:outcomeId>56b34a8b03c231.83157615</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Masters Course Module on Brain Diseases</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>BC80DC56-66B0-484B-9F84-A0AC9F98695F</gtr:id><gtr:impact>Establishment of new Masters Module at Lancaster University on Brain Diseases, which is also available as CPD course for Biomedical Scientists.</gtr:impact><gtr:outcomeId>fzRJss9ajmR</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Assistant Director of Centre for Ageing Research at Lancaster University</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2CD5D7AC-BD72-49BE-AA81-8D60F68F2BBD</gtr:id><gtr:outcomeId>MzbXpJH2Yev</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Research Council Executive of the Alzheimer's Society, UK</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A3AEB7AB-0CA2-43D2-9742-B9D5AB9B43DB</gtr:id><gtr:outcomeId>9BDBC97EBC3</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Steering Committee for DeNDRoN North West</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>9AC80FF1-AC3A-4617-AC57-17CE4A727041</gtr:id><gtr:outcomeId>35C31DF0E86</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have full ethical approval for collection of additonal CSF from any neurology patients undergoing lumbar puncture for routine clinical investigations (Royal Preston Hospital). These can be used for biomarker research. 

Ventricular CSF is being collected by ART Manchester Brain Bank.</gtr:description><gtr:id>947B1674-F653-4E01-AA4E-3807B0986812</gtr:id><gtr:impact>Publications 18989684 and 21856424.</gtr:impact><gtr:outcomeId>7A48FBB5C74</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CSF sample collection</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cross-sectional samples of blood plasma have been collected from approximately 1100 patients with neurodegenerative disorders and controls (with full ethical approval).</gtr:description><gtr:id>E074B2A6-83D0-4248-8806-DE4EF20BA7ED</gtr:id><gtr:impact>Publications 19823856, 18989684, 21865317. Prof. Kevin Morgan (Nottingham University), Prof. Stuart Pickering-Brown (Manchester University) are using samples for genetic research.</gtr:impact><gtr:outcomeId>52E01B9B917</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Cross-sectional samples of plasma</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Longitudinal samples of human blood plasma have been collected from 200 recently diagnosed patients with Parkinson's disease for biomarker studies.</gtr:description><gtr:id>77A3EA57-D6E2-4C0A-884F-366EE583FEA8</gtr:id><gtr:impact>As far as we are aware, this is a unique collection of clinical samples in the UK. Sample collection is continuing, and this material will be a valuable resource for the MRC-funded study, and for future investgation by ourselves and other collaborators. Samples used for publication 21865317.</gtr:impact><gtr:outcomeId>197B1DDDEBC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Longitudinal plasma samples from patients with Parkinson's Disease</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A luminex bead-based multiplex assay system has been purchased (September 2011) with a new equipment grant from Alzheimer's Research UK.</gtr:description><gtr:id>E8AF9279-AAE7-478A-B28E-F5DB687D7F3B</gtr:id><gtr:impact>Only just acquired.</gtr:impact><gtr:outcomeId>pnREa638i8j</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Liquichip Workstation</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New immunoassays developed to detect and quantify various forms of alpha-synuclein and TDP-43 in biological fluids</gtr:description><gtr:id>2122B963-D516-48B3-BD9F-CFAA91A38560</gtr:id><gtr:impact>Publications 18989684, 19823856, 21865317, 21856424. Visiting scientists from London University and Japan have used these assay techniques for their research.</gtr:impact><gtr:outcomeId>8CBF248D96C</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New assays for quantitative analysis of biomarkers in blood and CSF</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new statistical model has been developed by Prof. Peter Diggle and Dr. Gerwyn Green (Lancaster University) for analysis of data from longitudinal samples collected for alpha-synuclein investigations.</gtr:description><gtr:id>42143647-DEDA-4807-8504-06B92BBC3D2B</gtr:id><gtr:impact>Published paper 21865317 has used this statistical model for interpretation of biomarker data.</gtr:impact><gtr:outcomeId>0E9376EC2A0</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>New statistical model developed</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>742577C7-2049-43DD-A80E-E450A4F6CAC0</gtr:id><gtr:title>Phosphorylated a-synuclein as a potential biomarker for Parkinson's disease and related disorders.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a167fc920c3b2305bea269c5919bbaf"><gtr:id>0a167fc920c3b2305bea269c5919bbaf</gtr:id><gtr:otherNames>Foulds P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>pm_14027_27_22369370</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C4788D1-B8E5-442F-97FD-F498E9F96A28</gtr:id><gtr:title>Post mortem cerebrospinal fluid a-synuclein levels are raised in multiple system atrophy and distinguish this from the other a-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a273ec7dbc3852644f7448f046721a09"><gtr:id>a273ec7dbc3852644f7448f046721a09</gtr:id><gtr:otherNames>Foulds PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>V1ZnW7dStbH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C59D77D-5BD9-41D5-9975-06BBBEABF672</gtr:id><gtr:title>Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d7440212aeb6525fe46b7280a604200"><gtr:id>5d7440212aeb6525fe46b7280a604200</gtr:id><gtr:otherNames>Kasai T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>4ED65BBC456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>145D9F5C-09F3-446A-A688-4E1C7AA7DA6D</gtr:id><gtr:title>Phosphorylated a-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a273ec7dbc3852644f7448f046721a09"><gtr:id>a273ec7dbc3852644f7448f046721a09</gtr:id><gtr:otherNames>Foulds PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>Mb513ErJCi5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43F5494E-7AD2-4EEA-81B0-BC95073F103A</gtr:id><gtr:title>A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a273ec7dbc3852644f7448f046721a09"><gtr:id>a273ec7dbc3852644f7448f046721a09</gtr:id><gtr:otherNames>Foulds PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_14027_27_23985836</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>566E492B-F2DB-411F-9F57-AD73CD5EEF47</gtr:id><gtr:title>Parkinson disease: Progress towards a molecular biomarker for Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a167fc920c3b2305bea269c5919bbaf"><gtr:id>0a167fc920c3b2305bea269c5919bbaf</gtr:id><gtr:otherNames>Foulds P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>Ft9fahY58Hx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB86A58E-1CBA-473A-980E-0F3415B2D7BB</gtr:id><gtr:title>Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a273ec7dbc3852644f7448f046721a09"><gtr:id>a273ec7dbc3852644f7448f046721a09</gtr:id><gtr:otherNames>Foulds PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>D971327C67A</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601364</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>